# KIF5A and ALS: a clinical and genetic description of a case series and review of literature

**Authors:** Anna D’Amico, Roberta Cucunato, Giuseppe Schirò, Giuseppe Salemi, Paolo Ragonese, Vincenzo La Bella, Paolo Aridon, Marco D’Amelio

PMC · DOI: 10.1007/s10072-026-08885-w · Neurological Sciences · 2026-02-28

## TL;DR

This paper describes clinical and genetic features of patients with motor neuron disease linked to KIF5A gene variants, highlighting phenotypic variability and new mutations.

## Contribution

The study reports new KIF5A variants and their association with both familial and sporadic ALS cases.

## Key findings

- Eight patients with KIF5A variants were identified, including three novel mutations.
- Phenotypic variability was observed among patients with mutations in different regions of KIF5A.
- Some patients had co-occurring mutations in other ALS-related genes like FUS.

## Abstract

Approximately 10% of ALS (amyotrophic lateral sclerosis) cases show a family history, and the remaining 90% are sporadic. In 2018, through genome sequencing using two independent approaches, KIF5A was described as a novel ALS-associated gene. To describe clinical and genetic characteristics of a series of patients with motor neuron disease (MND), diagnosed at University Hospital of Palermo, carrying KIF5A variants. During 2019–2023, two hundred twenty-four patients with MND and healthy subjects with familial history of MND, underwent next-generation sequencing (NGS) for molecular analysis, including genetic testing for C9orf72 hexanucleotide-repeat expansion. The most mutated ALS genes, including KIF5A, were included in a NGS panel. Of the entire tested population, eight patients (including a brother and a sister) were found to carry KIF5A variants. Four patients had familial ALS, the other four were sporadic. Six patients were females (75%). Mean age at ALS onset was 59 years (33–75). Patients were evaluated according to the ALSFRS-revisited during follow-up visits. According to disease progression rate, five patients were defined as ∆FS ≤ 0.5 (slow-progressors), the remaining three patients showed a ∆FS > 1 (fast-progressors). Of the seven KIF5A variants, three are not already described in literature (respectively c.170 C > T, p.Thr57Met; c.2920T > G, p.Ser974Ala and c.2732 A > C, p.Lys911Thr). Two patients showed the association of variations in KIF5A with variations or mutations in other ALS genes, one of them carried a pathogenic variant of FUS (P525L). This study demonstrates phenotypic variability related to mutations in different regions of the same gene resulting in a susceptibility for the disease spectrum with different characteristics.

## Linked entities

- **Genes:** KIF5A (kinesin family member 5A) [NCBI Gene 3798], C9orf72 (C9orf72-SMCR8 complex subunit) [NCBI Gene 203228], FUS (FUS RNA binding protein) [NCBI Gene 2521]
- **Diseases:** ALS (MONDO:0004976), amyotrophic lateral sclerosis (MONDO:0004976), motor neuron disease (MONDO:0020128)

## Full-text entities

- **Genes:** DNAJC7 (DnaJ heat shock protein family (Hsp40) member C7) [NCBI Gene 7266] {aka DJ11, DJC7, TPR2, TTC2}, C9orf72 (C9orf72-SMCR8 complex subunit) [NCBI Gene 203228] {aka ALSFTD, DENND9, DENNL72, FTDALS, FTDALS1}, KLC1 (kinesin light chain 1) [NCBI Gene 3831] {aka KLC, KNS2, KNS2A}, KIF5B (kinesin family member 5B) [NCBI Gene 3799] {aka HEL-S-61, KINH, KNS, KNS1, UKHC}, KIF1B (kinesin family member 1B) [NCBI Gene 23095] {aka CMT2, CMT2A, CMT2A1, HMSNII, KLP, NBLST1}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, KIF5A (kinesin family member 5A) [NCBI Gene 3798] {aka ALS25, D12S1889, MY050, NEIMY, NKHC, SPG10}, SETX (senataxin) [NCBI Gene 23064] {aka ALS4, AOA2, SCAN2, SCAR1, STEX, Sen1}, DNAH8 (dynein axonemal heavy chain 8) [NCBI Gene 1769] {aka ATPase, SPGF46, hdhc9}, TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}
- **Diseases:** muscle weakness (MESH:D018908), dyspnea (MESH:D004417), psychiatric disorders (MESH:D001523), Alzheimer's disease (MESH:D000544), atrophic limb (MESH:D020966), atrophy (MESH:D001284), asthma (MESH:D001249), hyposthenia of the neck (MESH:D006258), spondylosis (MESH:D055009), Charcot-Marie-Tooth neuropathy type 2 (MESH:C535302), cirrhosis (MESH:D005355), spasticity (MESH:D009128), MND variant of disease (MESH:D004194), neurodegenerative disorders (MESH:D019636), swallowing and phonation disorder (MESH:D055154), dyslipidemia (MESH:D050171), pain (MESH:D010146), SPG (MESH:D010264), neurogenic distress (MESH:D012128), allelic disorders (MESH:D030342), neurological ( (MESH:D009461), fasciculations (MESH:D005207), cervicalgia (MESH:D019547), low back pain (MESH:D017116), hand (MESH:D006230), MND (MESH:D016472), gait disturbances (MESH:D020233), respiratory failure (MESH:D012131), left brachialgia (MESH:D018487), hypercapnia (MESH:D006935), dysarthria (MESH:D004401), FALS (MESH:D000073376), spinocerebellar ataxia (MESH:D020754), CMT (MESH:C537989), COVID-19 (MESH:D000086382), hernias (MESH:D006547), infection (MESH:D007239), weight loss (MESH:D015431), numbness (MESH:D006987), dysphagia (MESH:D003680), Amyotrophic lateral sclerosis (MESH:D000690), HCV (MESH:D006526), muscle cramps (MESH:D009120), leg spasms (MESH:D013035), axonal neuropathy (MESH:D020269), death (MESH:D003643), leg stiffness (MESH:C566112), limb disorders (MESH:D001259), hypertension (MESH:D006973), multiple sclerosis) and oncological diseases (MESH:D000072716), familial and sporadic ALS (MESH:C531617), migraine (MESH:D008881), hereditary spastic paraplegia (MESH:D015419), spastic paraparesis (MESH:D020336), dropped head (MESH:D000094222), ALS (MESH:D008113), Sars-Cov2 (MESH:D000094024), cognitive-behavioral impairments (MESH:D003072), VUS (MESH:D065309), gait impairment (MESH:D020234)
- **Chemicals:** PEG (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.Tyr38His, c.3020 + 1G > A, P525L, c.3052G > T, p.Arg716Gln, p.Arg423His, p.Arg588Gln, c.170 C > T, p.Ser974Ala, p.Asp853Asn, p.Thr585Ala, c.2993-3 C > A, p.Leu494Met, c.2920T > G, Lys653Arg, c.112T > C, c.1165 C > T, c.2732 A > C, p.Glu755Lys, c.1702G > A, p.Pro46Ala, p.Glu881Lys, p.Glu1028Asp, D232N, p.Gly235Glu, p.Glu251Lys

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948853/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12948853/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12948853/full.md

---
Source: https://tomesphere.com/paper/PMC12948853